Pfizer (PFE) Long-Term Investments (2009 - 2026)

Pfizer (PFE) has 18 years of Long-Term Investments data on file, last reported at $1.6 billion in Q1 2026.

• Quarterly Long-Term Investments fell 19.27% year-over-year to $1.6 billion in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $1.6 billion (down 19.27% YoY) and the FY2025 annual result came in at $1.6 billion, down 27.24% from the prior year.
• Long-Term Investments steadied at $1.6 billion in Q1 2026 per PFE's latest filing, from $1.6 billion in the prior quarter.
• Across five years, Long-Term Investments topped out at $16.0 billion in Q2 2022 and bottomed at $224.0 million in Q2 2025.
• The 5-year median for Long-Term Investments is $9.8 billion (2022), against an average of $8.0 billion.
• The widest annual swing landed in 2022, when Long-Term Investments jumped 87.23%; it then slumped 97.13% in 2025.
• Tracing PFE's Long-Term Investments over 5 years: stood at $10.8 billion in 2022, then surged by 41.98% to $15.4 billion in 2023, then slumped by 85.5% to $2.2 billion in 2024, then retreated by 27.24% to $1.6 billion in 2025, then rose by 0.31% to $1.6 billion in 2026.
• Per Business Quant, the three latest PFE Long-Term Investments figures stand at $1.6 billion (Q1 2026), $1.6 billion (Q4 2025), and $2.1 billion (Q3 2025).

Peer Comparison